EIKN (NASDAQ:EIKN) Rating Lowered to “Sell” at Wall Street Zen

EIKN (NASDAQ:EIKN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald started coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “overweight” rating for the company. Wedbush started coverage on shares of EIKN in a research note on Thursday, February 26th. They issued an “underperform” rating and a $7.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $29.00 target price for the company. Mizuho assumed coverage on shares of EIKN in a research report on Monday, March 2nd. They set an “outperform” rating and a $26.00 target price for the company. Finally, Bank of America initiated coverage on shares of EIKN in a report on Monday, March 2nd. They issued a “buy” rating and a $34.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.60.

EIKN Stock Down 1.1%

Shares of NASDAQ EIKN opened at $14.38 on Friday. EIKN has a 52 week low of $13.28 and a 52 week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.